|
시장보고서
상품코드
2076123
인간용 예방 백신 시장 : 백신 유형별, 기술 플랫폼별, 용도별, 지역별Prophylactic Human Vaccine Market, By Vaccine Type, By Technology Platform, By Application, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
인간용 예방 백신 시장은 2026년에 779억 달러로 추정되고 있으며, 2033년까지 1,153억 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 7.0%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 779억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.00% | 2033년 시장 규모 예측 : | 1,153억 달러 |
전 세계 예방용 인체 백신 시장에는 4가, 2가, 1가 및 이와 유사한 백신 유형에 걸친 제품들이 포함됩니다. 이 제품들은 소아 예방접종, 성인 예방접종, 고령자 예방접종 등 각 분야에서 활용되며, 다양한 최종사용자에게 채택되고 있습니다. 조직이 성과, 효율성, 비용 대비 효과를 점점 더 중시함에 따라 이러한 부문에서의 채용은 꾸준히 확대되고 있습니다.
시장 역학 :
주요 최종사용자 부문의 수요 증가, 효율성과 신뢰성 향상의 필요성, 그리고 지속적인 제품 혁신이 전 세계 예방용 인간 백신 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다. 소아 예방접종 및 성인 예방접종에서의 도입 확대가 이러한 추세를 더욱 강화하고 있습니다.
예를 들어 시장에 진출한 각 기업은 소아 예방접종 사용 사례를 위해 설계된 첨단 솔루션을 도입하고 있습니다. 또한 지속적인 기술 발전과 전략적 투자를 통해 예측 기간 중 시장에 진출한 기업에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 이 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 예방용 인체 백신 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 예방용 인간 백신 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 예방용 인간 백신 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 인간용 예방 백신 시장 : 백신 유형별, 2026-2033년
제5장 인간용 예방 백신 시장 : 기술 플랫폼별, 2026-2033년
제6장 인간용 예방 백신 시장 : 용도별, 2026-2033년
제7장 인간용 예방 백신 시장 : 지역별, 2026-2033년
제1장 경쟁 구도
제2장 섹션
KSA 26.07.09Prophylactic Human Vaccine Market is estimated to be valued at USD 77.90 billion in 2026 and is expected to reach USD 115.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 77.90 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 115.3 billion |
The global prophylactic human vaccine market includes offerings that span Quadrivalent, Bivalent, and Monovalent, and similar vaccine type categories. These are applied across Pediatric Immunization, Adult Vaccination, and Geriatric Vaccination and adopted by diverse end users. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from major end-use sectors, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global prophylactic human vaccine market. Broader adoption across Pediatric Immunization, and Adult Vaccination is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for Pediatric Immunization use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global prophylactic human vaccine market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Sanofi Pasteur; Pfizer Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Bharat Biotech International Limited; Serum Institute of India Pvt. Ltd.; Johnson & Johnson; Novavax, and Inc.; Sinovac Biotech Ltd.; BioNTech SE; AstraZeneca Plc, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global prophylactic human vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prophylactic human vaccine market.
Detailed Segmentation:
- Global Prophylactic Human Vaccine Market, By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
- Quadrivalent
- Bivalent
- Monovalent
- Pentavalent
- Others
- Global Prophylactic Human Vaccine Market, By Technology Platform (Revenue, USD Bn, 2021 - 2033)
- Live Attenuated
- Inactivated
- Recombinant
- mRNA-based
- Others
- Global Prophylactic Human Vaccine Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Pediatric Immunization
- Adult Vaccination
- Geriatric Vaccination
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Sanofi Pasteur; Pfizer Inc.; GlaxoSmithKline plc; Merck & Co.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Inc.; Bharat Biotech International Limited; Serum Institute of India Pvt. Ltd.; Johnson & Johnson; Novavax
- Inc.; Sinovac Biotech Ltd.; BioNTech SE; AstraZeneca Plc
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Technology Platform
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Prophylactic Human Vaccine Market By Vaccine Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Bivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Monovalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Pentavalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Prophylactic Human Vaccine Market By Technology Platform, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Recombinant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- mRNA-based
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Prophylactic Human Vaccine Market By Application, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Pediatric Immunization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adult Vaccination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Geriatric Vaccination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Prophylactic Human Vaccine Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology Platform, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology Platform, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology Platform, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology Platform, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology Platform, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Sanofi Pasteur
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bharat Biotech International Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sinovac Biotech Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
